Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


National Strategy For Biomedical Innovation Simmering On Hamburg’s Agenda

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA commissioner says all stakeholders need to come to the table to develop a path for maintaining U.S. preeminence in making medical discoveries and moving them through the pharmaceutical pipeline into patients’ hands.


Related Content

Recipe For Doubling Innovative Medicines Includes New Approval Pathway, FDA Management Changes
Swedish Boost For Life Sciences Innovation Resonates Around Europe


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts